Addition of Lithium to Radioactive Iodine Treatment With Improved Response in a Woman With Progressive Papillary Thyroid Carcinoma

ABSTRACT: Objective: Differentiated thyroid carcinoma (DTC) treatment includes surgery and therapy with radioactive iodine (RAI) (131I) of thyroid remnants and metastases. The objective of this report is to describe an improved response in a woman with progressive papillary thyroid carcinoma, and ad...

Full description

Bibliographic Details
Main Authors: Maríadel Mar Navarro-Pelayo Láinez, MD, Maria Angustias Muros de Fuentes, MD, PhD, Martín López de la Torre Casares, MD, PhD, José Manuel Llamas Elvira, MD, PhD
Format: Article
Language:English
Published: Elsevier 2016-01-01
Series:AACE Clinical Case Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2376060520302868
id doaj-f1d9cb9b483e47e188de9bb75ebfdd79
record_format Article
spelling doaj-f1d9cb9b483e47e188de9bb75ebfdd792021-04-30T07:24:14ZengElsevierAACE Clinical Case Reports2376-06052016-01-0122e96e99Addition of Lithium to Radioactive Iodine Treatment With Improved Response in a Woman With Progressive Papillary Thyroid CarcinomaMaríadel Mar Navarro-Pelayo Láinez, MD0Maria Angustias Muros de Fuentes, MD, PhD1Martín López de la Torre Casares, MD, PhD2José Manuel Llamas Elvira, MD, PhD3Department of Nuclear Medicine, and; Address correspondence to Dr. María del Mar Navarro-Pelayo Láinez, Department of Nuclear Medicine, Virgen de las Nieves University Hospital, Avenue Fuerzas Armadas, 2, 18014, Granada, Spain.Department of Nuclear Medicine, andDepartment of Endocrinology, Virgen de las Nieves University Hospital, Granada, Spain.Department of Nuclear Medicine, andABSTRACT: Objective: Differentiated thyroid carcinoma (DTC) treatment includes surgery and therapy with radioactive iodine (RAI) (131I) of thyroid remnants and metastases. The objective of this report is to describe an improved response in a woman with progressive papillary thyroid carcinoma, and adjuvant lithium carbonate therapy in order to enhance 131I efficacy.Methods: A young woman underwent total thyroidectomy with bilateral cervical lymph node dissection for a multicentric papillary carcinoma. Despite 8 therapeutic doses of 131I, the patient showed a negative 131I scan and increasing thyroglobulin values. After preparation with oral administration of 600 mg of lithium and a 15-day regimen of 300 mg (3 times/day), which was adjusted according to the patient's daily recorded serum lithium level, a dose of 150 mCi of 131I was administered on day 15.Results: After this procedure, the patient showed for 5 continuous years the lowest thyroglobulin levels observed during her follow-up, and she remains clinically and radiologically stable.Conclusion: In progressive, high-risk DTC with 131I-resistant metastatic disease, the combination of radioiodine with lithium in an adequately controlled protocol might be of benefit. Prospective studies comparing RAI therapy alone to RAI therapy plus lithium in similar groups of patients with DTC are needed to demonstrate that lithium with RAI therapy is superior to RAI therapy alone.Abbreviations: DTC = differentiated thyroid carcinoma RAI = radioactive iodine Tg = thyroglobulin TSH = thyroid-stimulating hormonehttp://www.sciencedirect.com/science/article/pii/S2376060520302868
collection DOAJ
language English
format Article
sources DOAJ
author Maríadel Mar Navarro-Pelayo Láinez, MD
Maria Angustias Muros de Fuentes, MD, PhD
Martín López de la Torre Casares, MD, PhD
José Manuel Llamas Elvira, MD, PhD
spellingShingle Maríadel Mar Navarro-Pelayo Láinez, MD
Maria Angustias Muros de Fuentes, MD, PhD
Martín López de la Torre Casares, MD, PhD
José Manuel Llamas Elvira, MD, PhD
Addition of Lithium to Radioactive Iodine Treatment With Improved Response in a Woman With Progressive Papillary Thyroid Carcinoma
AACE Clinical Case Reports
author_facet Maríadel Mar Navarro-Pelayo Láinez, MD
Maria Angustias Muros de Fuentes, MD, PhD
Martín López de la Torre Casares, MD, PhD
José Manuel Llamas Elvira, MD, PhD
author_sort Maríadel Mar Navarro-Pelayo Láinez, MD
title Addition of Lithium to Radioactive Iodine Treatment With Improved Response in a Woman With Progressive Papillary Thyroid Carcinoma
title_short Addition of Lithium to Radioactive Iodine Treatment With Improved Response in a Woman With Progressive Papillary Thyroid Carcinoma
title_full Addition of Lithium to Radioactive Iodine Treatment With Improved Response in a Woman With Progressive Papillary Thyroid Carcinoma
title_fullStr Addition of Lithium to Radioactive Iodine Treatment With Improved Response in a Woman With Progressive Papillary Thyroid Carcinoma
title_full_unstemmed Addition of Lithium to Radioactive Iodine Treatment With Improved Response in a Woman With Progressive Papillary Thyroid Carcinoma
title_sort addition of lithium to radioactive iodine treatment with improved response in a woman with progressive papillary thyroid carcinoma
publisher Elsevier
series AACE Clinical Case Reports
issn 2376-0605
publishDate 2016-01-01
description ABSTRACT: Objective: Differentiated thyroid carcinoma (DTC) treatment includes surgery and therapy with radioactive iodine (RAI) (131I) of thyroid remnants and metastases. The objective of this report is to describe an improved response in a woman with progressive papillary thyroid carcinoma, and adjuvant lithium carbonate therapy in order to enhance 131I efficacy.Methods: A young woman underwent total thyroidectomy with bilateral cervical lymph node dissection for a multicentric papillary carcinoma. Despite 8 therapeutic doses of 131I, the patient showed a negative 131I scan and increasing thyroglobulin values. After preparation with oral administration of 600 mg of lithium and a 15-day regimen of 300 mg (3 times/day), which was adjusted according to the patient's daily recorded serum lithium level, a dose of 150 mCi of 131I was administered on day 15.Results: After this procedure, the patient showed for 5 continuous years the lowest thyroglobulin levels observed during her follow-up, and she remains clinically and radiologically stable.Conclusion: In progressive, high-risk DTC with 131I-resistant metastatic disease, the combination of radioiodine with lithium in an adequately controlled protocol might be of benefit. Prospective studies comparing RAI therapy alone to RAI therapy plus lithium in similar groups of patients with DTC are needed to demonstrate that lithium with RAI therapy is superior to RAI therapy alone.Abbreviations: DTC = differentiated thyroid carcinoma RAI = radioactive iodine Tg = thyroglobulin TSH = thyroid-stimulating hormone
url http://www.sciencedirect.com/science/article/pii/S2376060520302868
work_keys_str_mv AT mariadelmarnavarropelayolainezmd additionoflithiumtoradioactiveiodinetreatmentwithimprovedresponseinawomanwithprogressivepapillarythyroidcarcinoma
AT mariaangustiasmurosdefuentesmdphd additionoflithiumtoradioactiveiodinetreatmentwithimprovedresponseinawomanwithprogressivepapillarythyroidcarcinoma
AT martinlopezdelatorrecasaresmdphd additionoflithiumtoradioactiveiodinetreatmentwithimprovedresponseinawomanwithprogressivepapillarythyroidcarcinoma
AT josemanuelllamaselviramdphd additionoflithiumtoradioactiveiodinetreatmentwithimprovedresponseinawomanwithprogressivepapillarythyroidcarcinoma
_version_ 1721498545575428096